CD44 and breast cancer: Therefore, elemene was found to reduce the CD44+ CD24−/low cell ratio and reverse breast cancer resistance to Adriamycin by reducing the serum pellet-free rate of MCF-7/ADM cells and the expression of BCRP and P-gp genes/proteins [67].